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Background: Hypertension has been considered an inflammatory disease. Oxidized lipoproteins and anti-oxidized LDL (anti-oxLDL) antibodies 
(Abs) have been detected in plasma in response to blood pressure (BP) elevation, suggesting the participation of the adaptive immune system. 
Treatment of hypertension may act on the immune response by decreasing oxidation stimuli. However, this issue has not been fully addressed. Thus, 
we have here analyzed anti-ox LDL Abs in untreated (naïve) hypertensive patients shortly after initiation of anti-hypertensive therapeutic regimens.
Methods: Titers of anti-oxLDL Abs were measured in subjects with recently-diagnosed hypertension on stage 1 (n=94), in primary prevention 
of coronary disease, with no other risk factors, and naïve of anti-hypertensive medication at entry. The study was randomized, double-blind, with 
subjects assigned to receive perindopril, hydrochlorothiazide or indapamide for 12 weeks, with additional perindopril if necessary to achieve BP 
control (open-label). Investigators were unaware of treatment assignment. Abs against copper-oxidized LDL were measured by ELISA, with results 
expressed in IR (index of reactivity). TBARS, hs-CRP and vasoreactivity (FMD) were also assessed. GLM-repeated measures evaluated treatment 
effects within and between groups.
Results: Twelve-week anti-hypertensive treatment reduced both office-based and 24-h ambulatory BP measurements (P<0.0005). The decrease in 
BP was accompanied by reduction in thiobarbituric acid-reactive substances (P<0.05), increase in anti-oxLDL Ab titers (P<0.005), and improvement 
in flow-mediated dilation (FMD) (P<0.0005), independently of treatment arm. While BP and lipid peroxidation were reduced, favorable changes in 
anti-oxLDL titers and FMD were seen.
Conclusions: We observed that anti-oxLDL antibody titers increase after anti-hypertensive therapy in primary prevention when achieving BP 
targets. Our results are in agreement with the concept that propensity to oxidation is increased by essential hypertension and anti-oxLDL Abs may be 
protective and potential biomarkers for the follow-up of hypertension treatment.
